HOUSTON--(BUSINESS WIRE)--Stem Cell Innovations (SCLL.OB) (SCI) noted that two recent government panels, one in the US and one in the UK, advocate the use of cell-based assays for toxicity testing. The Company’s human liver-based ACTIVTox® and stem cell-based PluriCell™ systems are specifically designed for this purpose.
